UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)

Annals of oncology, 2024-03, Vol.35 (3), p.267-275

2024

Volltextzugriff (PDF)

Approach to Management of Thrombotic Thrombocytopenic Purpura at University of Cincinnati

Advances in Hematology, 2013, Vol.2013 (2013), p.23-26

2013

Volltextzugriff (PDF)

Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

Cancer investigation, 2009-10, Vol.27 (9), p.932-936

2009

Volltextzugriff (PDF)

Atypical B12 Deficiency with Nonresolving Paraesthesia

Case reports in oncological medicine, 2013-01, Vol.2013 (2013), p.1-3

2013

Volltextzugriff (PDF)

Waldenstrom’s Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash

Case reports in oncological medicine, 2013-01, Vol.2013 (2013), p.1-3

2013

Volltextzugriff (PDF)

P1.22-05 Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S246

2023

Volltextzugriff (PDF)

EP13.07-07 Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S709

2023

Volltextzugriff (PDF)

EP1.01-23 SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S920-S921

2019

Volltextzugriff (PDF)

P1.01-64 Predictive Value of K-Ras Subset Mutations and PD-L1 in Pulmonary Sarcomatoid Carcinoma (PSC)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S384-S384

2019

Volltextzugriff (PDF)

Geographical Clustering of Pancreatic Cancers in the Northeast Nile Delta Region of Egypt

Archives of environmental contamination and toxicology, 2006-07, Vol.51 (1), p.142-148

2006

Volltextzugriff (PDF)

P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S650-S650

2019

Volltextzugriff (PDF)

EP1.01-67 Molecular Profiling of K-Ras and Its Subtypes in NSCLC Patients with Liver Metastasis

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S938-S938

2019

Volltextzugriff (PDF)

P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S464-S464

2019

Volltextzugriff (PDF)

PS06.06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1583-S1584

2017

Volltextzugriff (PDF)

PS06.06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC): Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1583-S1584

2017

Volltextzugriff (PDF)

PS02.11 Is There any Cardiotoxicity with Anti-PD/PDL 1 Immunotherapy? A Meta-Analysis of Randomized Clinical Trials: Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1568-S1568

2017

Volltextzugriff (PDF)

PS02.11 Is There any Cardiotoxicity with Anti-PD/PDL 1 Immunotherapy? A Meta-Analysis of Randomized Clinical Trials

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1568

2017

Volltextzugriff (PDF)

P2.01-015 Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxel–Based Therapy

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2074-S2075

2017

Volltextzugriff (PDF)

P2.01-014 ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel–Based Therapy in Patients with NSCLC and ECOG PS 2

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2074-S2074

2017

Volltextzugriff (PDF)

PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials: Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1567-S1568

2017

Volltextzugriff (PDF)

PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1567-S1568

2017

Volltextzugriff (PDF)

Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2

Annals of oncology, 2016-10, Vol.27, p.vi443-vi443

2016

Volltextzugriff (PDF)

EML4-ALK in NSCLC: The OSU Experience

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18014-e18014

2011

Volltextzugriff (PDF)

Modeling uncertain load and wind power in the electric energy systems

2012 IEEE Power and Energy Society General Meeting, 2012, p.1-8

2012

Volltextzugriff (PDF)

SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness: EP1.01-23

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S920-S921

2019

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(137)
Französisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)

Approach to Management of Thrombotic Thrombocytopenic Purpura at University of Cincinnati

Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

Atypical B12 Deficiency with Nonresolving Paraesthesia

Waldenstrom’s Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash

P1.22-05 Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases

EP13.07-07 Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others

EP1.01-23 SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness

P1.01-64 Predictive Value of K-Ras Subset Mutations and PD-L1 in Pulmonary Sarcomatoid Carcinoma (PSC)

Geographical Clustering of Pancreatic Cancers in the Northeast Nile Delta Region of Egypt

P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)

EP1.01-67 Molecular Profiling of K-Ras and Its Subtypes in NSCLC Patients with Liver Metastasis

P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy

PS06.06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC)

PS06.06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC): Topic: Medical Oncology

PS02.11 Is There any Cardiotoxicity with Anti-PD/PDL 1 Immunotherapy? A Meta-Analysis of Randomized Clinical Trials: Topic: Medical Oncology

PS02.11 Is There any Cardiotoxicity with Anti-PD/PDL 1 Immunotherapy? A Meta-Analysis of Randomized Clinical Trials

P2.01-015 Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxel–Based Therapy

P2.01-014 ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel–Based Therapy in Patients with NSCLC and ECOG PS 2

PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials: Topic: Medical Oncology

PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials

Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2

EML4-ALK in NSCLC: The OSU Experience

Modeling uncertain load and wind power in the electric energy systems

SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness: EP1.01-23

Suchergebnisse filtern